Table 2.

Patients With Hepatitis C Virus RNA Lower than the Level of Quantification^*

Time Point	Sofosbuvir + Ledipasvir n=20	Sofosbuvir + Ledipasvir + GS-9669 n=20	Sofosbuvir + Ledipasvir + GS-9451 n=20
	12 wk	6 wk	6 wk
During Treatment –n (% [95% CI])
Day 7	2 (10[1–31])	0 0	5 (25[9–49])
Week 2	6 (30[12–54])	6 (30[12–54])	9 (45[23–68])
Week 4	17 (85[62–97])	20 (100[83–100])	20 (100[83–100])
Week 6	–	20 (100[83–100])	20 (100[83–100])
Week 8	20 (100[83–100])	–	–
Week 12	20 (100[83–100])	–	–
Post Treatment Period –n (%[95% CI])
Week 4	20 (100[83–100])	19 (95[75–100])	20 (100[83–100])
Week 12	20 (100[83–100])	19 (95[75–100])	19** (95[75–100])

^*The limit of HCV RNA quantification was 43 IU/mL

^**one patient who achieved SVR4 was incarcerated subsequent to this visit. Although records were available at 12 weeks post-therapy, a special session of the NIAID IRB including a prisoner representative decided that data from subsequent time points could not be reported.